Drilldown: Medicines
More actions
Use the filters below to narrow your results.
generic:
brand:
None (35) ·
(none, never marketed) (1) ·
Dalmane (1) ·
Doral (1) ·
Doriden (1) ·
Halcion (1) ·
Hetlioz (1) ·
Imovane (1) ·
Lunesta (1) ·
Mogadon (1) ·
Nembutal (1) ·
Placidyl (1) ·
ProSom (1) ·
Quaalude (1) ·
Restoril (1) ·
Rohypnol (1) ·
Rozerem (1) ·
Seconal (1) ·
Sonata (1) ·
Tamiflu (1) ·
THIP (1) ·
Valtrex (1) ·
Versed (1) ·
Xyrem (1) ·
Zovirax (1)
classes: (Click arrow to add another value)
mechanism:
None (4) ·
5-HT2A agonist (15) ·
5-HT2A agonist; 5-HT3 antagonist (1) ·
5-HT2A agonist; minor psilocybin mushroom alkaloid (1) ·
5-HT2A agonist; primarily auditory effects (1) ·
5-HT2A agonist; sigma-1 agonist (1) ·
Extremely potent GABAA positive allosteric modulator (1) ·
GABAA positive allosteric modulator (15) ·
GABAA positive allosteric modulator (non-benzodiazepine) (3) ·
GABAA positive allosteric modulator; very long half-life (1) ·
GABAA potentiator (1) ·
GABAA potentiator and direct activator (2) ·
GABAB agonist; GHB receptor agonist (1) ·
Melatonin receptor agonist (2) ·
Monoamine releasing agent; 5-HT2A agonist; MAO inhibitor (1) ·
Positive allosteric modulator of the GABA<sub>A</sub> receptor at the benzodiazepine binding site; increases frequency of Cl<sup>−</sup> channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects. (1) ·
Potent 5-HT2A agonist; sigma-1 agonist (1) ·
Prodrug of 4-HO-DET; 5-HT2A agonist (1) ·
Prodrug of 4-HO-DiPT; 5-HT2A agonist (1) ·
Prodrug of 4-HO-MET; 5-HT2A agonist (1) ·
Prodrug of 4-HO-MiPT; 5-HT2A agonist (1) ·
Prodrug of psilocin; 5-HT2A agonist (1) ·
Selective GABAA agonist (extrasynaptic delta subunit) (1) ·
'"`UNIQ--vote-000005D0-QINU`"' Selectivity comes from the viral-kinase-only initial phosphorylation step, which is why uninfected cells generate minimal active drug'"`UNIQ--ref-000005D1-QINU`"'. Dose-adjust by renal function; rare crystalline nephropathy with rapid IV acyclovir. (1)
uses:
None (55) ·
No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) ·
'"`UNIQ--vote-000005D2-QINU`"', '"`UNIQ--vote-000005D3-QINU`"', '"`UNIQ--vote-000005D4-QINU`"', '"`UNIQ--vote-000005D5-QINU`"' (1) ·
'"`UNIQ--vote-00000909-QINU`"', '"`UNIQ--vote-0000090A-QINU`"', '"`UNIQ--vote-0000090B-QINU`"', '"`UNIQ--vote-0000090C-QINU`"', '"`UNIQ--vote-0000090D-QINU`"', '"`UNIQ--vote-0000090E-QINU`"' (1) ·
'"`UNIQ--vote-00000E91-QINU`"', '"`UNIQ--vote-00000E92-QINU`"', '"`UNIQ--vote-00000E93-QINU`"' (1)
starting dose:
None (55) ·
Initial genital herpes 1 g PO BID × 10 days; recurrent 500 mg BID × 3 days; suppression 500 mg-1 g PO daily; zoster 1 g TID × 7 days (1) ·
Initial genital herpes 400 mg PO TID × 7-10 days; episodic 800 mg TID × 2 days; suppression 400 mg BID; herpes zoster 800 mg 5×/day × 7 days; HSV encephalitis 10 mg/kg IV q8h × 14-21 days (1) ·
No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1) ·
Treatment: 75 mg PO BID × 5 days (adult); pediatric weight-based; prophylaxis: 75 mg PO once daily × 7-10 days (1)
preparations:
None (55) ·
200, 400, 800 mg tablets; 200 mg capsules; 200 mg/5 mL suspension; 500, 1000 mg IV vials; 5% cream and ointment (topical) (1) ·
30, 45, 75 mg capsules; 6 mg/mL oral suspension (1) ·
500 mg, 1 g tablets (1) ·
Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1)
fda max:
routes:
onset:
None (55) ·
Symptom relief within 24-48 hours (1) ·
Symptom relief within 24-48 hours of starting episodic treatment (1) ·
Symptom shortening detectable within 24-48 hours of starting (small absolute benefit; ~1 day reduction in symptom duration) (1) ·
~20–40 min PO; faster sublingual/intranasal. (1)
duration:
halflife:
None (55) ·
Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) ·
~3 hours (acyclovir, the active metabolite); longer in renal impairment'"`UNIQ--ref-000005D6-QINU`"' (1) ·
~3 hours; significantly prolonged in renal impairment'"`UNIQ--ref-0000090F-QINU`"' (1) ·
~6-10 hours (oseltamivir carboxylate, the active metabolite)'"`UNIQ--ref-00000E94-QINU`"' (1)
bioavailability:
None (55) ·
Not formally characterized in humans. (1) ·
~20% (oral; valacyclovir prodrug raises this to ~55%)'"`UNIQ--ref-00000910-QINU`"' (1) ·
~55% bioavailability of acyclovir after valacyclovir oral (vs ~20% from oral acyclovir directly)'"`UNIQ--ref-000005D7-QINU`"' (1) ·
~75% (oral, as the active carboxylate after hepatic esterase activation)'"`UNIQ--ref-00000E95-QINU`"' (1)
pregnancy:
None (55) ·
Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) ·
Generally used when influenza treatment is indicated; pregnancy is a recognized risk factor for severe influenza.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Widely used in pregnancy for HSV/VZV indications; reassuring registry data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Widely used in pregnancy when antiviral indicated; reassuring registry data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 59 results in range #1 to #59.